Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy for Renal Cell Carcinoma

被引：23
作者：
Crispen, Paul L. [1 ]
Blute, Michael L. [2 ]
机构：
[1] Univ Kentucky, Dept Surg, Lexington, KY 40513 USA
[2] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA
来源：
CURRENT UROLOGY REPORTS | 2012年 / 13卷 / 01期
关键词：
Cytoreductive nephrectomy; Surgery; Targeted therapy; Metastasectomy; Renal cell carcinoma; Treatment; Kidney diseases; INTERFERON-ALPHA; SUNITINIB; SURGERY; SURVIVAL; TUMOR;
D O I：
10.1007/s11934-011-0225-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
With the advent of targeted therapy for the treatment of metastatic renal cancer, the routine use of cytoreductive nephrectomy has been questioned. However, available data suggest that cytoreductive nephrectomy remains an integral part of treatment in properly selected patients. This review details the rationale for the continued use of cytoreductive nephrectomy in acceptable surgical candidates in the era of targeted therapy.
引用
收藏
页码：38 / 46
页数：9
相关论文
共 44 条
[1]  
Abdollah F, 2011, ANN SURG ON IN PRESS
[2]   Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma [J].
Abel, E. Jason ;
Culp, Stephen H. ;
Tannir, Nizar M. ;
Matin, Surena F. ;
Tamboli, Pheroze ;
Jonasch, Eric ;
Wood, Christopher G. .
EUROPEAN UROLOGY, 2011, 59 (01) :10-15
[3]   Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment [J].
Abel, E. Jason ;
Culp, Stephen H. ;
Matin, Surena F. ;
Tamboli, Pheroze ;
Wallace, Michael J. ;
Jonasch, Eric ;
Tannir, Nizar M. ;
Wood, Christopher G. .
JOURNAL OF UROLOGY, 2010, 184 (05) :1877-1881
[4]  
Abel EJ, 2011, EUR UROL IN PRESS
[5]   Survival After Complete Surgical Resection of Multiple Metastases From Renal Cell Carcinoma [J].
Alt, Angela L. ;
Boorjian, Stephen A. ;
Lohse, Christine M. ;
Costello, Brian A. ;
Leibovich, Bradley C. ;
Blute, Michael L. .
CANCER, 2011, 117 (13) :2873-2882
[6]   Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy [J].
Barbastefano, Juan ;
Garcia, Jorge A. ;
Elson, Paul ;
Wood, Laura S. ;
Lane, Brian R. ;
Dreicer, Robert ;
Campbell, Steven C. ;
Rini, Brian I. .
BJU INTERNATIONAL, 2010, 106 (09) :1266-1269
[7]   Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials [J].
Bex, Axel ;
Jonasch, Eric ;
Kirkali, Ziya ;
Mejean, Arnaud ;
Mulders, Peter ;
Oudard, Stephane ;
Patard, Jean-Jacques ;
Powles, Thomas ;
van Poppel, Hendrik ;
Wood, Christopher G. .
EUROPEAN UROLOGY, 2010, 58 (06) :819-828
[8]  
Chapin BF, 2011, EUR UROL IN PRESS
[9]  
Chiong E, 2009, FUTURE ONCOL, V5, P859, DOI [10.2217/fon.09.52, 10.2217/FON.09.52]
[10]   Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy [J].
Choueiri, Toni K. ;
Garcia, Jorge A. ;
Elson, Paul ;
Khasawneh, Mohamad ;
Usman, Saif ;
Golshayan, Ali Reza ;
Baz, Rachid C. ;
Wood, Laura ;
Rini, Brian I. ;
Bukowski, Ronald M. .
CANCER, 2007, 110 (03) :543-550
12345